TOMI Environmental Solutions (TOMZ) Q2 FY26 earnings call: guidance and Q&A

TOMI's strategic initiatives, introduced in late 2024 and early 2025, are validating their focus, driving growth across BIT Solution sales, mobile equipment, single applicators, and support services. BIT Solution sales exceeded $700,000 in the first half of the year, positioning the company for higher full-year sales than the prior two years. The emphasis on applicator sales, which totaled nearly $400,000 year-to-date, represents an 1,100% increase year-over-year, demonstrating customer expansion of the patented cold plasma technology and reinforcing the consumable-driven razor-and-blade model.

The company is making significant strides on the regulatory front, including advancing its 510(k) submission process with the FDA for medical device applications, which would expand its addressable market. New EPA registration for AgriMist broadens approved use sites to indoor grown plants and fruits, including applications up to the day of harvest. SteraMist has also secured approvals in numerous European countries and played a key role in NSF's decision to shift biosafety cabinet decontamination rules towards performance-based criteria, where SteraMist excels.

TOMI delivered SteraMist iHP chambers to a Fortune 500 medical device manufacturer, marking a milestone for integration with its stand-alone system. Collaborations are underway with two additional partners to develop a next-generation, all-in-one fully autonomous iHP chamber for various high-value items. New partnerships were secured with a top-tier American health company, a private research university, government agencies, and food safety customers, alongside expanding domestic and international distribution networks, including in the UK, Poland, Germany, Puerto Rico, and South America.

Disciplined overhead management led to a 10% year-over-year reduction in quarterly operating expenses to $1.63 million, primarily from G&A savings. This cost control, combined with $1.92 million in net proceeds from an equity line of credit, strengthened the balance sheet, expanding working capital to $1.82 million and increasing cash and cash equivalents to $322,000. The company also improved its net loss by 69% year-over-year to $382,000 and is actively remediating historic material weaknesses with dedicated CPA oversight and robust financial controls.

The pending merger with Carbonium Core, valued at a combined $180 million, includes a $10 million minimum concurrent financing condition expected to transform the combined company's balance sheet. This merger aligns with securing U.S. critical mineral supply chains, particularly for nuclear graphite and lithium. Dr. Shane articulated a vision for SteraMist in biodefense, leveraging robotics and drones for autonomous preventive disinfection, emphasizing preparedness for future biological threats and aiming to grow the team to 200 employees in the next three years.